Logo
x

Search

Subscribe Now

Neuromyelitis Optica Spectrum Disorder

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021

Horizon Presents Results of Uplizna (inebilizumab-cdon) in N-MOmentum Trial for NMOSD at AAN 2021

  • April 6, 2021
Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

Genentech to Present New Data of Enspryng (satralizumab-mwge) for Neuromyelitis Optica Spectrum Disorder at MSVirtual2020

  • September 10, 2020
Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

Roche's Enspryng (satralizumab) Receives Health Canada Approval for Neuromyelitis Optica Spectrum Disorder

  • September 1, 2020
Roche's Enspryng (satralizumab-mwge) Receives the US FDA's Approval for Neuromyelitis Optica Spectrum Disorder

Roche's Enspryng (satralizumab-mwge) Receives the US FDA's Approval for Neuromyelitis Optica Spectrum Disorder

  • August 17, 2020
Roche's Enspryng (satralizumab) Receives MHLW's Approval for Neuromyelitis Optica Spectrum Disorder in Japan

Roche's Enspryng (satralizumab) Receives MHLW's Approval for Neuromyelitis Optica Spectrum Disorder in Japan

  • June 29, 2020
Viela Bio's Uplizna (inebilizumab-cdon) Receives the US FDA's Approval to Treat Neuromyelitis Optica Spectrum Disorder (NMOSD)

Viela Bio's Uplizna (inebilizumab-cdon) Receives the US FDA's Approval to Treat Neuromyelitis Optica Spectrum Disorder (NMOSD)

  • June 11, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.